Navigation Links
Generic Erosion of Established Branded Atypical Antipsychotics Will Cause the Schizophrenia Drug Market To Decline More Than $1 Billion by 2013
Date:12/2/2009

WALTHAM, Mass., Dec. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that generic erosion of several established branded atypical antipsychotics will cause the schizophrenia drug market to decrease from $6.3 billion in 2008 to $5.2 billion in 2013 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Schizophrenia finds that the patent expiries of Janssen's Risperdal Consta and Invega, AstraZeneca's Seroquel, Bristol-Myers Squibb/Otsuka Pharmaceutical's Abilify, Eli Lilly's Zyprexa and Pfizer's Geodon/Zeldox will be the key factors driving a 20 percent decrease in the overall schizophrenia drug market. However, as a result of the uptake of emerging therapies -- primarily depot formulations -- the market will increase modestly from $5.2 billion in 2013 to $5.6 billion in 2018.

The launch of new depot formulations of atypical antipsychotics will partially offset the decline in the schizophrenia market and will offer more-convenient treatment options for patients. Janssen's depot formulation of Invega, Invega Sustenna, will experience the greatest market success of all depot formulations, with peak-year major-market sales in excess of $500 million.

"Depot formulations such as Invega Sustenna will offer advantages in dosing and administration compared with the only marketed atypical depot formulation -- Janssen's Risperdal Consta," said Decision Resources Analyst Sandra Chow, M.Sc. "Emerging depot formulations will command premium pricing and, in 2018, will account for nearly one-third of the overall schizophrenia drug market."

Interviewed experts indicate that because most current antipsychotics function through similar mechanisms of action and are not completely effective in all patients, the development of therapies with novel mechanisms of action remains a key unmet need in schizophrenia treatment. Eli Lilly's LY-2140023 will be the first agent with a novel mechanism of action to reach the market, launching in 2013 in the United States and in 2014 in Europe. The report finds that LY-2140023, which will be largely used in conjunction with currently available agents, will provide physicians with an effective new treatment option for patients inadequately controlled on other antipsychotic regimens.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


For more information, contact:

Decision Resources                        Decision Resources, Inc.
Christopher Comfort                       Elizabeth Marshall
781-296-2597                              781-296-2563
ccomfort@dresources.com                   emarshall@dresources.com

SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
2. Watson Launches Generic Biaxin(R) XL
3. Perrigo and Partner Cobrek Confirms Filing for Generic Version of Evoclin(R) and Announcement of Lawsuit by Stiefel
4. Generic Substitutes Less Effective/Safe Than Branded Medications in Treating Lower Urinary Tract Symptoms
5. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
6. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
7. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
8. Bundling Two Generic Low-Cost Heart Drugs Prevents Heart Attack and Stroke in Large, Diverse Population, Observational Clinical Study Shows
9. Hospira, Celltrion, Enter Business Cooperation Agreement to Develop and Market Biogeneric Drugs
10. Perrigo Confirms Filing for Generic Version of Mens Rogaine(R) Foam
11. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/8/2017)... Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... reports its financial results for the second quarter ended ... the second quarter 2017 and to date: ... development programs for the Company,s lead project, BL-8040: ... study with BL-8040 as novel stem cell mobilization treatment ...
(Date:8/7/2017)... Insightin Health, provider of data-driven decision-making ... announced the selection of Michael Wood ... as of February 2017. In this role, Wood will ... our clients. Wood brings with him more than ... analytics within the healthcare industry. Wood formerly served ...
(Date:8/7/2017)... Aug. 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Saban as president, effective Aug. 7, 2017. ... decided to pursue other interests and will serve as president ... Paul has served us in multiple leadership roles since he ... Jun. 2015 and has provided decisive, strategic leadership which continues ...
Breaking Medicine Technology:
(Date:8/18/2017)... ... August 18, 2017 , ... Hernandez Insurance Agencies, a ... throughout the greater DC region, is inaugurating a “New Leash On Life” charity ... and training them to be companions for veterans in need. , The Semper ...
(Date:8/18/2017)... Humble, TX (PRWEB) , ... August 18, 2017 ... ... insurance management and financial planning firm that serves residential and commercial clients in ... a charity drive to raise community support for the fight against cancer. , ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that rids the ... efforts with its product now available through Jet.com. , After 25 years of ... powdered drink is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether ...
(Date:8/18/2017)... ... , ... “Three Narrow Roads”: a vivid and provocative look into the narrow ... Burnett King Sr., is currently the pastor-teacher-visionary at Simply the WORD Church, a global ... a track-and-field program geared towards youth. , King shares, “When I take time to ...
(Date:8/18/2017)... ... ... “Prompted By Love”: a love story thrown into doubt by untimely news. “Prompted ... Nettles has devoted her life to ministry since the age of 12 when she ... however, not fulfilled until 2014 when "The Color of Roses" was published. After ...
Breaking Medicine News(10 mins):